Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Sugars × Sarcoma × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 11 Plasma cell 4 Thoracic 3 Other 3 Lymphoid 3 Genitourinary 3 Gastrointestinal 3 Other hematologic neoplasm 2 Head & Neck 2 Tumor-Agnostic 1 Sarcoma 1 Other neoplasm 1 Myeloid 1 Gynecologic 1 Dermatologic 1 CNS 1

Conditions

Interventions

Radiotherapy 132 Temozolomide 103 Cyclophosphamide 102 Doxorubicin 101 Filgrastim 71 Ifosfamide 63 Imatinib Mesylate 62 Etoposide 60 Bevacizumab 51 Vincristine 48 Irinotecan 41 Gemcitabine 41 Peripheral Blood Stem Cell Transplantation 37 Methotrexate 36 Radiation 33 Cisplatin 31 Carboplatin 31 pazopanib 30 Busulfan 29 fludarabine phosphate 28 Trabectedin 28 Melphalan 26 Sirolimus 24 Docetaxel 23 Sunitinib 22 Magnetic Resonance Spectroscopy 22 Carmustine 22 sargramostim 21 Surgical Procedures, Operative 21 Granulocyte Colony-Stimulating Factor 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02606461 2023-01-23

SEAL

Karyopharm Therapeutics Inc

Phase 2/3 Completed

342 enrolled 36 charts

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡